Work

ZANUBRUTINIB (ZANU) VERSUS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT‐NAïVE (TN) CLL/SLL: EXTENDED FOLLOW‐UP OF THE SEQUOIA STUDY

Year: 2023
Type: article
Abstract: cohort.Rates of atrial fibrillation remained low, and no new safety signals were identified.Zanu continues to be well tolerated over time, with low rates of treatment discontinuation, and remains a valuable treatment option for TN CLL/SLL.
Language: English
Subfield: Genetics
Field: Medicine
Open Access status: bronze
OpenAlex ID: W4380079293
FWCI: 1.848
Cites:
Cited by: 13
Related to: 10